Drug Sponsors

NantHealth acquires Harris Healthcare Solutions

Friday, July 17, 2015 09:26 AM

NantHealth, a subsidiary of NantWorks, has completed the acquisition of Harris Corp’s commercial Healthcare Solutions business, a clinical systems integration innovator. Harris retained its government healthcare services business.

More... »


Celgene to acquire Receptos for $7.2B

Wednesday, July 15, 2015 08:58 AM

Celgene, headquartered in Summit, N.J., has agreed to acquire Receptos, a biopharmaceutical company based in San Diego. Celgene will pay $232 per share in cash, or a total of approximately $7.2 billion, net of cash acquired.

More... »


PHE drug development to transfer to new state-owned company

Friday, July 10, 2015 09:35 AM

Public Health England will transfer its drug development and production to a new company, Porton Biopharma. The transfer of Public Health England’s (PHE’s) clinical drug development and production capability into a stand-alone, state-owned biopharmaceutical limited company has been approved by the Secretary of State for Health.

More... »

Sorrento, NantBioScience form joint venture

Friday, July 10, 2015 09:29 AM

Sorrento Therapeutics, a clinical stage oncology company, and NantBioScience, a majority owned subsidiary of NantWorks, have established a joint venture to focus on the development of first-in-class small molecules addressing drivers of cancer growth, including cancer stem cells. ‎Sorrento will contribute key small molecule programs (lead inhibitors of the proto-oncogenes c-Myc, and the master metabolism regulator HIF-1 alpha, and an inducer of the tumor suppressor cytokine TRAIL) to the joint venture, which will be 60% owned by NantBioScience and 40% owned by Sorrento, and funded accordingly.

More... »

Horizon Pharma proposes to acquire Depomed for $3B

Wednesday, July 8, 2015 09:01 AM

Horizon Pharma, a Dublin, Ireland-based biopharmaceutical company, has proposed to acquire all outstanding shares of Depomed, a U.S. specialty pharmaceutical company, for a per share consideration of $29.25 in an all-stock, tax-free exchange valued at approximately $3 billion. Horizon's proposal represents a premium of 42% to the closing price of Depomed on July 6. The transaction, if consummated, would be immediately and substantially accretive to Horizon's adjusted diluted earnings per share.

More... »

Baxalta launches focused on orphan diseases and underserved conditions

Thursday, July 2, 2015 08:53 AM

Baxalta has launched as a global biopharmaceutical company dedicated to delivering transformative therapies to patients with orphan diseases and underserved conditions. The company continues to advance in hematology and immunology and seeks to expand its oncology portfolio for patients with limited treatment options. Baxalta plans to launch 20 new products by 2020, leveraging the company’s existing global capabilities and footprint in more than 100 countries.

More... »

Entasis launches with a drug-resistant bacterial infections portfolio

Thursday, July 2, 2015 08:47 AM

Entasis Therapeutics, a Waltham, Mass.-based company, has launched with a portfolio of diverse, innovative investigational drugs for the treatment of serious drug-resistant bacterial infections.

More... »

Actelion creates Vaxxilon together with the Max Planck Society

Wednesday, July 1, 2015 10:38 AM

Actelion, a biopharmaceutical company based in Switzerland, has created a start-up, together with the Max Planck Society, in synthetic carbohydrate vaccines. The new company, Vaxxilon, aims to discover, develop, and commercialize synthetic carbohydrate vaccines.

More... »

Transgene plans restructuring to focus on R&D, cuts 120 jobs

Wednesday, July 1, 2015 10:21 AM

Transgene, a France-based biotechnology company specializing in immunotherapies for cancer and infectious diseases, plans to modify its vertical integration model and to implement a restructuring in order to maintain its competitiveness and to ensure a sustainable future.

More... »

AMAG Pharmaceuticals acquires Lumara Health's Maternal Health Business

Wednesday, July 1, 2015 10:20 AM

AMAG Pharmaceuticals, a Massachusetts-based specialty pharmaceutical company, has completed the acquisition of Lumara Health, a St. Louis, Mo.-based specialty pharmaceutical company with a particular focus on maternal health. The transaction was announced on September 29, 2014 and included upfront consideration of $600 million in cash and 3,209,971 shares of AMAG common stock, and additional contingent consideration of up to $350 million based on the achievement of sales milestones. 

More... »

CWWeekly

July 27

AB Science warned about putting study volunteers in danger

FDA, Google unite to detect search-data adverse events

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

July

Integrated research partnerships build momentum
Research function provides infrastructure, leverages large pool of health systems' patients and data

'Right to Try' laws challenge clinical trial process
20 states pass, 20 more pending allowing access to study drugs without FDA and IRB approval

Already a subscriber?
Log in to your digital subscription.

Purchase the July issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

June

TransCelerate Biopharma turns three
High-profile consortium has made inroads fixing wasteful practices, but it still has more work ahead

Pharma industry improves its tarnished reputation
Delivering innovation, social responsibility will help rebuild trust

Already a subscriber?
Log in to your digital subscription.

Purchase the June issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs